1	SUPPORTING INFORMATION				
2					
3	Deep tissue imaging with highly fluorescent NIR nanocrystals after systematic host screening				
4 5 6	Fabian H.L. Starsich <sup>1,†</sup> , Pascal Gschwend <sup>1,†</sup> , Anton Sergeyev <sup>2</sup> , Rachel Grange <sup>2</sup> and Sotiris E. Pratsinis <sup>1,*</sup>				
7					
8 9 10	<sup>1</sup> Particle Technology Laboratory, Institute of Process Engineering, Department of Mechanical and Process Engineering, ETH Zurich, Sonneggstrasse 3, CH-8092 Zurich, Switzerland				
11 12 13	<sup>2</sup> Optical Nanomaterials Group, Institute for Quantum Electronics, Department of Physics, ETH Zürich, Auguste-Piccard-Hof 1, CH-8093 Zurich, Switzerland				
14	<sup>†</sup> Authors contributed equally to this work				
15					
16 17 18	*Corresponding author: Sotiris E. Pratsinis; Tel.: +41 44 632 31 80; fax: +41 44 632 15 95; e-mail: sotiris.pratsinis@ptl.mavt.ethz.ch				
19					
20	14.09.2017				
21					
22	Submitted to:				
23	Chemistry of Materials				
24	and revised				
25					
26					
20 27					
28					
-0 29					



1

**Figure S1**: Integrated emission of the  ${}^{4}F_{9/2} \rightarrow {}^{4}I_{3/2}$  transition of  $Nd^{3+}$  (850-1000 nm) as a function of doping content for three different particles. The total nanoparticle mass was kept constant.





5

6 Figure S2: Primary particle sizes  $(d_{BET})$  of as-prepared Nd-doped (1 at%) particles



2 Figure S3: XRD spectra of as-prepared oxides



*Figure S4*: XRD spectra of annealed oxides



2 Figure S5: XRD spectra of as-prepared phosphates



5 Figure S6: XRD spectra of annealed phosphates



2 Figure S7: XRD spectra of as-prepared vanadates



5 Figure S8: XRD spectra of annealed vanadates

- '



2 Figure S9: Primary particle size (small (solid line) and large (broken line) axes) distributions and the

- 3 corresponding geometric average diameters,  $d_g$ , and standard deviations,  $\sigma_g$ , as determined by image
- 4 analysis of (a) as-prepared and (b) annealed  $BiVO_4:Nd^{3+}$  nanoparticles.



1

**2** Figure S10: (a) Emission spectra of  $NdVO_4$  with  $d_{XRD} = 30$ , 53 and 78 nm. (b) The integrated emission

3 intensity (850-1000 nm) as a function of crystal size ( $d_{XRD}$ ) together with a linear fit. (c) Slope of the linear

4 fits as shown in (b) for all host crystals using:

$$Slope = \frac{\frac{I_{3} - I_{1}}{I_{1}}}{\frac{d_{XRD,3} - d_{XRD,1}}{d_{XRD,1}}}$$

- 5 The values were normalized to remove differences in absolute emission intensity and be able to compare the
- 6 relative change of integrated emission intensity with crystal size.



*Figure S11*: Excitation spectra monitoring the integrated emission from 850-1000 nm. The optimized

```
3 excitation wavelength (black circles), which is not dependent on the particle size,<sup>40,41</sup> was used to scale the
```

```
4 emission intensity gathered under excitation from the 808 nm laser diode.
```



**2** *Figure S12:* Lifetime measurement of  $BiVO_4$ : Nd<sup>3+</sup> in powder form. Inset shows parameters of double

*exponential fit and calculation of average lifetime.* 



*Figure S13:* Hydrodynamic size distribution of bare, unfunctionalized BiVO<sub>4</sub>:Nd (annealed 2 hours at

- 6 600°C) measured by dynamic light scattering. The suspension was prepared at a particle concentration of
- 7 0.1 mg mL<sup>-1</sup> of PBS buffer solution. The measurement was performed immediately after sonication.



- **2** *Figure S14: Exemplary quantification of fluorescence by*  $BiVO_4$ :  $Nd^{3+}$  *in Figure 4c at 3 (a) and 15 mm (b)*
- *depth*.
- *Table S1:* Average and integrated intensities for each boxed area in Figure S14 that were used to obtain the
- *data points in Figure 4c.*

	Area (# pixel)	Average intensity	Integrated intensity		Area (# pixel)	Average intensity	Integrated intensity
Area 1	3721	233.96	870'593	Area 1	3721	60.68	225'800
Area 2	6480	127.83	828'319	Area 2	6480	38.26	247'932
Area 3	9963	74.96	746'972	Area 3	9963	28.16	280'600
Total	20'164		2'445'884	Total	20'164		754'332
Background	20'164	7.02	141'675	Background	20'164	5.17	104'297
Total - Background			2'304'209	Total - Background			650'035



2 *Figure S15:* (a) Initial NIR-fluorescence images of surgical dye ICG (left) and BiVO<sub>4</sub>:Nd<sup>3+</sup> (right) patterned

3 in a square, through 5 mm of optical phantom under tissue-friendly 808 nm excitation  $(0.2 \text{ W/cm}^2)$ . (b)

4 Intensity along the x-axis through the center of the squared patterns.

Pattern (contrast enhanced area) edges were defined as the average intensity between the maximum within
the contrast enhanced area and adjacent background. This further led to the exact location of the pattern
center (halfway between the edges), pattern widths (d1 and d2) and distance (x) between the two patterns
(ICG and BiVO<sub>4</sub>:Nd<sup>3+</sup>) in pixels. As the distance x is also known in µm it was used to convert all other

9 distances. The pattern widths were thereafter compared to the actual widths and the resolution was defined

10 as the difference (ICG: 77  $\mu$ m, BiVO<sub>4</sub>:Nd<sup>3+</sup>: 119  $\mu$ m).

11

1

12



*Figure S16:* Cytotoxicity of  $BiVO_4$ :  $Nd^{3+}$  nanoparticles tested with murine macrophages (RAW 264.7). 



Values from Panas et al.<sup>59</sup> were added as comparison. 

Table S2: Annealing conditions for all flame-made fluorescent nanoparticles (oxides, phosphates, 1 2

## vanadates)

Material	Temperature [°C]	Duration [h]	d <sub>XRD</sub> [nm]	Crystal structure
	as-prepared	-	24.3	Tetragonal
Bi <sub>2</sub> O <sub>3</sub>	500	4	46.7	Monoclinic
	600	1	52.8	Monoclinic
	as-prepared	-	17.7	Cubic
CeO <sub>2</sub>	800	2	23.2	Cubic
	1000	2	45.9	Cubic
	as-prepared	-	15.7	Monoclinic
$Gd_2O_3$	800	2	28.5	Monoclinic
	1000	2	79.8	Monoclinic
	-	-	37.2	Hexagonal
La <sub>2</sub> O <sub>3</sub>	800	2	41.2	Hexagonal
	900	2	47.6	Hexagonal
	as-prepared	-	18.4	Hexagonal
Nd <sub>2</sub> O <sub>3</sub>	800	2	36.6	Hexagonal
	1000	2	86.9	Hexagonal
	as-prepared	-	11.3	Monoclinic
$Y_2O_3^*$	as-prepared	-	17.3	Monoclinic
	800	2	23.0	Monoclinic
	as-prepared	-	29.5	Cubic
$Y_{2}O_{3}^{*}$	1000	2	48.0	Cubic
	1000	2	119.2	Cubic
	as-prepared	-	17.8	Monoclinic
BiPO <sub>4</sub>	500	4	21.2	Monoclinic
	600	2	27.2	Monoclinic
	as-prepared	-	-	Monoclinic
CePO4	600	2	11.0	Monoclinic
	800	2	22.5	Monoclinic
	1000	2	42.4	Monoclinic
	as-prepared	-	-	Monoclinic
GdPO4	800	2	14.1	Monoclinic
	900	2	16.0	Monoclinic
	1000	2	27.5	Monoclinic

	as-prepared	-	-	Monoclinic
LaPO	800	2	27.2	Monoclinic
	1000	2	53.8	Monoclinic
	1200	2	81.9	Monoclinic
	as-prepared	-	-	Monoclinic
NdPO	800	2	28.8	Monoclinic
1101 04	900	2	31.6	Monoclinic
	1000	2	98.6	Monoclinic
	as-prepared	-	-	Tetragonal
YPO.	900	2	18.6	Tetragonal
1104	1000	2	20.8	Tetragonal
	1200	2	33.0	Tetragonal
	as-prepared	-	-	Amorphous
	300	2	26.2	Tetragonal
BiVO <sub>4</sub>	500	4	38.1	Monoclinic
	600	1	43.5	Monoclinic
	600	2	62.3	Monoclinic
	as-prepared	-	22.6	Tetragonal
CeVO <sub>4</sub>	600	2	71.3	Tetragonal
	600	4	101.7	Tetragonal
	as-prepared	-	24.2	Tetragonal
GdVO <sub>4</sub>	600	2	42.1	Tetragonal
	600	4	53.3	Tetragonal
	as-prepared	-	24.8	Monoclinic
LaVO <sub>4</sub>	600	2	64.1	Monoclinic
	600	4	103.1	Monoclinic
	as-prepared	-	29.8	Tetragonal
NdVO <sub>4</sub>	600	2	53.2	Tetragonal
	600	4	78.4	Tetragonal
	as-prepared	-	22.9	Tetragonal
YVO <sub>4</sub>	600	2	33.7	Tetragonal
	600	4	37.6	Tetragonal
b	*		*	•

Missing  $d_{XRD}$  values are due to bad match with reference spectra.  $*Y_2O_3$  was produced with various flame conditions and different precursor solvents to achieve monoclinic or cubic crystal phase<sup>58</sup>.